# Neoantigen-based Peptide Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After Second-line Treatment

> **NCT06751901** · PHASE2 · RECRUITING · sponsor: **The First Affiliated Hospital of Nanchang University** · enrollment: 10 (estimated)

## Conditions studied

- Advanced NSCLC

## Interventions

- **RADIATION:** Radiotherapy
- **DRUG:** PD-1 inhibitor
- **DRUG:** Neoantigen-based peptide vaccine

## Key facts

- **NCT ID:** NCT06751901
- **Lead sponsor:** The First Affiliated Hospital of Nanchang University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-03-11
- **Primary completion:** 2026-03-10
- **Final completion:** 2026-06-10
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2024-12-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06751901

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06751901, "Neoantigen-based Peptide Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After Second-line Treatment". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06751901. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*